-
公开(公告)号：US20240209083A1
公开(公告)日：2024-06-27
申请号：US18481884
申请日：2023-10-05
发明人： Xiao Min SCHEBYE , Mark J. SELBY , Michelle Minhua HAN , Christine BEE , Andy X. DENG , Anan CHUNTHARAPAI , Brigitte DEVAUX , Huiming LI , Paul O. SHEPPARD , Alan J. KORMAN , Daniel F. ARDOUREL , Ekaterina DEYANOVA , Richard Y. HUANG , Guodong CHEN , Michelle KUHNE , Hong-An TRUONG
CPC分类号： C07K16/2803 , A61K47/6849 , A61P35/00 , C07K16/2818 , C07K16/2827 , C07K16/2878 , C07K16/30 , C07K16/3046 , G01N33/57492 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/732 , C07K2317/734 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
-
公开(公告)号：US20220275091A1
公开(公告)日：2022-09-01
申请号：US17693975
申请日：2022-03-14
发明人： Sean E. DOYLE , Mark J. SELBY , Eric CHADWICK
摘要： Provided are methods and compositions for treating cancer using an effective amount of a PD-1 antagonist (e.g., an antibody) in combination with a TIM-4 antagonist (e.g., an antibody).
-
公开(公告)号：US20180164321A1
公开(公告)日：2018-06-14
申请号：US15578874
申请日：2016-06-02
发明人： Xi-Tao WANG , Olufemi A. ADELAKUN , Anne C. LEWIN , Alan J. KORMAN , Mark J. SELBY , Changyu WANG , Haichun HUANG , Karla A. HENNING , Nils LONBERG , Mohan SRINIVASAN , Michelle Minhua HAN , Guodong CHEN , Richard Y. HUANG , Indrani CHAKRABORTY , Susan Chien-Szu WONG , Huiming LI
IPC分类号： G01N33/574 , C07K16/28
摘要： Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.
-
公开(公告)号：US20210340250A1
公开(公告)日：2021-11-04
申请号：US16616569
申请日：2018-05-30
发明人： Alan J. KORMAN , Nils LONBERG , Mark J. SELBY , Jeffrey JACKSON
摘要： Provided are methods for clinical treatment of malignant tumors (e.g., advanced solid tumors) using a combination of an anti-LAG-3 antibody, an anti-PD-1 antibody, and an immunotherapeutic agent.
-
公开(公告)号：US20210009692A1
公开(公告)日：2021-01-14
申请号：US17018241
申请日：2020-09-11
发明人： Alan J. KORMAN , Nils LONBERG , David J. FONTANA , Andres A. GUTIERREZ , Mark J. SELBY , Katherine LEWIS
摘要： Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.
-
公开(公告)号：US20200299400A1
公开(公告)日：2020-09-24
申请号：US16612867
申请日：2018-05-24
发明人： Nils LONBERG , Alan J. KORMAN , Mark J. SELBY , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Michelle Minhua HAN , Ming LEI , Liang SCHWEIZER , Sandra V. HATCHER , Arvind RAJPAL
IPC分类号： C07K16/28
摘要： Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
-
公开(公告)号：US20200268901A1
公开(公告)日：2020-08-27
申请号：US16849757
申请日：2020-04-15
发明人： Nils LONBERG , Alan J. KORMAN , Mark J. SELBY , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Michelle Minhua HAN , Ming LEI , Liang SCHWEIZER , Sandra V. HATCHER , Arvind RAJPAL
IPC分类号： A61K47/68 , A61K39/395 , C07K16/00 , C07K16/28 , C07K16/30
摘要： Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
-
公开(公告)号：US20190298816A1
公开(公告)日：2019-10-03
申请号：US16351995
申请日：2019-03-13
IPC分类号： A61K39/00 , A61K39/395 , C07K16/28 , A61P35/00
摘要： The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.
-
公开(公告)号：US20190248893A1
公开(公告)日：2019-08-15
申请号：US16316991
申请日：2017-07-13
发明人： Xiao Min SCHEBYE , Mark J. SELBY , Michelle Minhua HAN , Christine BEE , Andy X. DENG , Anan CHUNTHARAPAI , Brigitte DEVAUX , Huiming LI , Paul O. SHEPPARD , Alan J. KORMAN , Daniel F. ARDOUREL , Ekaterina DEYANOVA , Richard Y. HUANG , Guodong CHEN , Michelle KUHNE , Hong-An TRUONG
IPC分类号： C07K16/28 , A61K47/68 , A61P35/00 , G01N33/574
CPC分类号： C07K16/2803 , A61K47/6849 , A61K2039/505 , A61K2039/507 , A61P35/00 , C07K16/2818 , C07K16/2827 , C07K16/2878 , C07K16/30 , C07K16/3046 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/732 , C07K2317/734 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N33/57492
摘要： Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
-
公开(公告)号：US20180312553A1
公开(公告)日：2018-11-01
申请号：US15895655
申请日：2018-02-13
IPC分类号： C07K14/435 , C07K16/28
CPC分类号： C07K14/435 , A61K2039/505 , C07K16/2818 , C07K16/2875 , C07K16/2878 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2317/72 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2319/30
摘要： The present disclosure provides a method for enhancing the anti-tumor efficacy of an Fc fusion protein which binds specifically to a target, e.g., a co-inhibitory or co-stimulatory receptor of ligand, on a T cell in a subject afflicted with a cancer or a disease caused by an infectious agent and alters the activity of the immunomodulatory target, thereby potentiating an endogenous immune response against cells of the cancer or the infectious agent, wherein the method comprises selecting, designing or modifying the Fc region of the Fc fusion protein so as to enhance the binding of said Fc region to an activating Fc receptor (FcR). The disclosure also provides an Fc fusion protein produced by said method and its use in treating a subject afflicted with a cancer or a disease caused by an infectious agent.
-
-
-
-
-
-
-
-
-
搜索结果
42 条记录 (耗时 0.043 秒)
